Lipid-based nanovesicles for nanomedicine

被引:232
|
作者
Grimaldi, N. [1 ,2 ]
Andrade, F. [1 ,3 ]
Segovia, N. [1 ,3 ]
Ferrer-Tasies, L. [1 ,3 ]
Sala, S. [1 ,3 ]
Veciana, J. [1 ,3 ]
Ventosa, N. [1 ,3 ]
机构
[1] Campus Univ Bellaterra, Inst Ciencia Mat Barcelona ICMAB CSIC, Cerdanyola Del Valles 08193, Spain
[2] Campus Univ Bellaterra, Nanomol Technol SA, Modul Recerca B, Cerdanyola Del Valles 08193, Spain
[3] CIBER BBN, Madrid, Spain
关键词
NONIONIC SURFACTANT VESICLES; LARGE UNILAMELLAR VESICLES; ULTRADEFORMABLE DRUG CARRIERS; ENHANCED TRANSDERMAL DELIVERY; IN-VITRO CHARACTERIZATION; PH-SENSITIVE LIPOSOMES; TARGETED DELIVERY; TOPICAL DELIVERY; OCULAR DELIVERY; PHYSICOCHEMICAL PROPERTIES;
D O I
10.1039/c6cs00409a
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Molecular self-assembly has enabled the fabrication of biologically inspired, advanced nanostructures as lipid-based nanovesicles (L-NVs). The oldest L-NVs, liposomes, have been widely proposed as potential candidates for drug delivery, diagnostic and/or theranostic applications and some liposome-based drug products have already stepped from the lab-bench to the market. This success is attributed to their ability to encapsulate both hydrophobic and/or hydrophilic molecules, efficiently carry and protect them within the body and finally deliver them at the target site. These positive features are also coupled with high biocompatibility. However, liposomes still present some unsolved drawbacks, such as poor colloidal stability, short shelf-life, restricted and expensive conditions of preparation because of the inherent nature of their fundamental constituents (phospholipids). The new tools available in the self-assembly of controlled molecules have significantly advanced the field of L-NV design and synthesis, and non-liposomal L-NVs have been recently developed; this new generation of nanovesicles can represent a paradigm shift in nanomedicine: they may complement liposomes, showing their advantages and overcoming most of their drawbacks. Clearly, being still young, their rocky way to the clinic first and then to the market has just started and it is still long, but they have all the potentialities to reach their objective target. The purpose of this review is to first present the large plethora of L-NVs available, focusing on this new generation of non-liposomal L-NVs and showing their similarities and differences with respect to their ancestors (liposomes). Since the overspread of a nanomaterial to the market is also strongly dependent on the availability of technological-scale preparation methods, we will also extensively review the current approaches exploited for L-NV production. The most cutting-edge approaches based on compressed fluid (CF) technologies will be highlighted here since they show the potential to represent a game-change in the production of L-NVs, favouring their step from the bench to the market. Finally, we will briefly discuss L-NV applications in nanomedicine, looking also for their future perspectives.
引用
收藏
页码:6520 / 6545
页数:26
相关论文
共 50 条
  • [1] Nanomedicine for Cancer: Lipid-Based Nanostructures for Drug Delivery and Monitoring
    Namiki, Yoshihisa
    Fuchigami, Teruaki
    Tada, Norio
    Kawamura, Ryo
    Matsunuma, Satoshi
    Kitamoto, Yoshitaka
    Nakagawa, Masaru
    ACCOUNTS OF CHEMICAL RESEARCH, 2011, 44 (10) : 1080 - 1093
  • [2] Lipid conjugate dissociation analysis improves the in vivo understanding of lipid-based nanomedicine
    van Os, Winant L.
    Wielaert, Laura
    Alter, Claudio
    Davidovic, David
    Sachl, Radek
    Kock, Thomas
    Gonz, Urimare Ugueto
    Arias-Alpizar, Gabriela
    Vigario, Fernando Lozano
    Knol, Renzo A.
    Kuster, Rick
    Romeijn, Stefan
    Mora, Nestor Lopez
    Detampel, Pascal
    Hof, Martin
    Huwyler, Jorg
    Kros, Alexander
    JOURNAL OF CONTROLLED RELEASE, 2024, 371 : 85 - 100
  • [3] Advances in lipid-based pulmonary nanomedicine for the management of inflammatory lung disorders
    Kumar, Manish
    Jha, Abhishek
    Bharti, Kanchan
    Parmar, Gourav
    Mishra, Brahmeshwar
    NANOMEDICINE, 2022, 17 (12) : 913 - 934
  • [4] Lipid-Based Nanovesicles for Simultaneous Intracellular Delivery of Hydrophobic, Hydrophilic, and Amphiphilic Species
    Zacheo, Antonella
    Bizzarro, Luca
    Blasi, Laura
    Piccirillo, Clara
    Cardone, Antonio
    Gigli, Giuseppe
    Ragusa, Andrea
    Quarta, Alessandra
    FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY, 2020, 8
  • [5] Fundamental Aspects of Lipid-Based Excipients in Lipid-Based Product Development
    Nakmode, Deepa
    Bhavana, Valamla
    Thakor, Pradip
    Madan, Jitender
    Singh, Pankaj Kumar
    Singh, Shashi Bala
    Rosenholm, Jessica M.
    Bansal, Kuldeep K.
    Mehra, Neelesh Kumar
    PHARMACEUTICS, 2022, 14 (04)
  • [6] Microfluidic Device-Enabled Mass Production of Lipid-Based Nanoparticles for Applications in Nanomedicine and Cosmetics
    Matsuura-Sawada, Yuka
    Maeki, Masatoshi
    Nishioka, Takaaki
    Niwa, Ayuka
    Yamauchi, Jun
    Mizoguchi, Masashi
    Wada, Koichi
    Tokeshi, Manabu
    ACS APPLIED NANO MATERIALS, 2022, 5 (06) : 7867 - 7876
  • [7] Lipid-based cosmeceuticals
    Compton, David L.
    INFORM - International News on Fats, Oils and Related Materials, 2006, 17 (12): : 793 - 795
  • [8] Exploring Curcumin-Loaded Lipid-Based Nanomedicine as Efficient Targeted Therapy for Alzheimer's Diseases
    Far, Bahareh Farasati
    Safaei, Maryam
    Pourmolaei, Ali
    Adibamini, Shaghyegh
    Shirdel, Shiva
    Shirdel, Shabnam
    Emadi, Reza
    Kaushik, Ajeet Kumar
    ACS APPLIED BIO MATERIALS, 2024, 7 (06): : 3535 - 3555
  • [9] Oral Lipid-Based Nanomedicine for the Inhibition of the cGAS-STING Pathway in Inflammatory Bowel Disease Treatment
    Guilbaud, Leo
    Chen, Cheng
    Domingues, Ines
    Kavungere, Espoir K.
    Marotti, Valentina
    Yagoubi, Hafsa
    Zhang, Wunan
    Malfanti, Alessio
    Beloqui, Ana
    MOLECULAR PHARMACEUTICS, 2025,
  • [10] Lipid-Based Nanoparticles in the Clinic and Clinical Trials: From Cancer Nanomedicine to COVID-19 Vaccines
    Thai Thanh Hoang Thi
    Suys, Estelle J. A.
    Lee, Jung Seok
    Nguyen, Dai Hai
    Park, Ki Dong
    Truong, Nghia P.
    VACCINES, 2021, 9 (04)